Abbott Laboratories (NYSE:ABT) Given New $130.00 Price Target at Raymond James Financial

Abbott Laboratories (NYSE:ABT) had its price target lowered by Raymond James Financial from $146.00 to $130.00 in a report issued on Friday,MarketScreener reports. The brokerage currently has an “outperform” rating on the healthcare product maker’s stock. Raymond James Financial’s target price indicates a potential upside of 19.61% from the company’s current price.

Several other research firms have also recently weighed in on ABT. Jefferies Financial Group upped their price objective on shares of Abbott Laboratories from $145.00 to $149.00 and gave the stock a “buy” rating in a research report on Thursday, October 16th. Piper Sandler decreased their price objective on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research note on Friday. Barclays raised their target price on Abbott Laboratories from $162.00 to $169.00 and gave the company an “overweight” rating in a report on Monday, January 5th. Wells Fargo & Company upped their price objective on Abbott Laboratories from $142.00 to $146.00 and gave the stock an “overweight” rating in a research report on Thursday, October 16th. Finally, Mizuho boosted their target price on Abbott Laboratories from $135.00 to $140.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 14th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $143.37.

Abbott Laboratories Price Performance

Shares of NYSE ABT traded up $0.08 during midday trading on Friday, reaching $108.69. The company’s stock had a trading volume of 2,307,181 shares, compared to its average volume of 8,972,974. The company has a market cap of $189.00 billion, a P/E ratio of 13.65, a P/E/G ratio of 2.00 and a beta of 0.72. Abbott Laboratories has a fifty-two week low of $105.78 and a fifty-two week high of $141.23. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70. The business’s 50 day moving average price is $125.23 and its two-hundred day moving average price is $128.54.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting analysts’ consensus estimates of $1.50. The firm had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The company’s revenue was up 4.4% on a year-over-year basis. During the same quarter last year, the company earned $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Institutional Trading of Abbott Laboratories

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Abbott Laboratories by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock valued at $23,502,644,000 after buying an additional 2,977,715 shares during the last quarter. State Street Corp boosted its stake in shares of Abbott Laboratories by 0.9% in the 2nd quarter. State Street Corp now owns 78,354,270 shares of the healthcare product maker’s stock valued at $10,656,964,000 after purchasing an additional 689,517 shares during the last quarter. Capital International Investors raised its stake in Abbott Laboratories by 2.5% during the third quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock worth $8,251,974,000 after buying an additional 1,478,076 shares during the last quarter. Geode Capital Management LLC boosted its position in Abbott Laboratories by 3.8% during the second quarter. Geode Capital Management LLC now owns 38,293,067 shares of the healthcare product maker’s stock valued at $5,184,589,000 after acquiring an additional 1,390,554 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Abbott Laboratories in the 2nd quarter worth about $3,026,180,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Several sell?side analysts kept constructive ratings and still see meaningful upside — Piper Sandler cut its price target to $135 but remains “overweight,” and BTIG trimmed its target to $140 while keeping a “buy” call, signaling continued analyst confidence despite the pullback. Benzinga
• Positive Sentiment: Med tech (devices) and Established Pharmaceuticals delivered strong growth (double?digit devices, mid?single to high single pharma), which management says helped offset weakness in other segments and supports the company’s multi?year growth thesis. Blockonomi
• Positive Sentiment: Market commentators view the pullback as a potential buying opportunity for long?term investors because Abbott remains a cash?generative Dividend King with capacity for buybacks and continued margin improvement. MarketBeat
• Neutral Sentiment: Adjusted EPS of $1.50 matched consensus, showing underlying earnings resilience even as revenues lagged; GAAP results included items that lowered headline net income. Press Release
• Neutral Sentiment: Company guidance: Q1 2026 adjusted EPS of $1.120–1.180 (below the ~1.20 consensus) and FY 2026 adjusted EPS of $5.55–5.80 (around consensus). Guidance tempered near?term expectations but keeps mid/longer?term growth intact. Press Release
• Negative Sentiment: Revenue missed Street estimates (~$11.46–11.5B reported vs. ~$11.8–11.9B expected); the Nutrition business declined sharply (near?9% year?over?year) and Diagnostics weakened (lower COVID testing and volatility), which triggered the market sell?off. Reuters Blockonomi
• Negative Sentiment: Unusual bearish positioning: intraday put option volume spiked sharply, indicating heavy hedging or speculative bearish bets that can amplify downward price moves. (Reported market activity)
• Negative Sentiment: Regulatory/legal overhang: documents show India regulators are scrutinizing supply of a codeine?based cough syrup tied to abuse investigations, introducing potential reputational and compliance risk. Reuters

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.